Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Cerevel Therapeutics Holdings Inc

Healthcare US CERE

NoneUSD
0.00(0%)

Last update at 2024-09-11T10:46:33.366196Z

Day Range

--
LowHigh

52 Week Range

19.5943.59
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap7530.12M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-484.52301M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.73

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -351.35100M -225.33400M -152.16600M -128.34400M -
Minority interest - - - - -
Net income -351.51100M -222.44600M -152.14200M -128.38900M -
Selling general administrative 87.59M 58.24M 45.81M 33.17M -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 4.90M 2.73M 0.40M 0.18M -
Ebit -372.75100M -222.82900M -149.51300M -83.46300M -483.32400M
Ebitda -367.84800M -220.09800M -149.11600M -36.84400M -
Depreciation and amortization 4.90M 2.73M 0.40M 46.62M -
Non operating income net other 6.88M -5.39300M -3.05000M - -
Operating income -367.84800M -220.09800M -149.11600M -83.46300M -
Other operating expenses 367.85M 220.10M 149.12M 83.46M -
Interest expense 9.62M 0.16M 2.65M 91.32M 0.00000M
Tax provision 0.16M 0.00000M -0.02400M 0.04M -
Interest income 9.62M 0.16M 0.22M 1.55M -
Net interest income 9.62M 0.16M 0.22M 1.55M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.16M -2.88800M -0.02400M 0.04M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 367.85M 220.10M 149.12M 83.46M -
Cost of revenue - - - - -
Total other income expense net 16.50M -5.23600M -3.05000M -44.88100M -
Discontinued operations - - - - -
Net income from continuing ops -351.51100M -225.33400M -152.14200M -128.38900M -
Net income applicable to common shares -351.51100M -225.33400M -148.27100M -128.38900M -463.63600M
Preferred stock and other adjustments - - -3.87100M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1243.30M 1017.82M 688.92M 445.27M 120.81M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 10.68M 13.62M 12.33M 6.94M 0.07M
Total liab 569.55M 496.58M 110.19M 60.75M 42.98M
Total stockholder equity 673.75M 521.24M 578.73M 384.52M 77.82M
Deferred long term liab - 0.29M 0.48M - 1.49M
Other current liab 76.91M 59.60M 0.38M 0.27M 0.07M
Common stock 0.02M 0.02M 0.01M 0.01M 0.00600M
Capital stock 0.02M 0.02M 0.01M 0.01M 0.00600M
Retained earnings -1400.59700M -967.75500M -616.24400M -390.91000M -244.29800M
Other liab - - 33.54M 0.24M 2.29M
Good will - - - - -
Other assets - 4.76M 6.93M 6.09M 6.24M
Cash 990.97M 136.52M 193.02M 383.62M 79.55M
Cash and equivalents - - - - -
Total current liabilities 92.18M 72.56M 42.54M 29.55M 14.88M
Current deferred revenue - - 28.43M 22.25M 10.10M
Net debt -510.18700M 230.15M -156.47100M -350.61800M -51.14000M
Short term debt 3.40M 2.90M 2.44M 2.04M 2.59M
Short long term debt - - - - -
Short long term debt total 480.78M 366.67M 36.55M 33.01M 28.41M
Other stockholder equity 2072.55M 1485.88M 1195.94M 775.42M 322.12M
Property plant equipment - 27.47M 51.70M 48.62M 27.49M
Total current assets 1006.94M 905.65M 578.02M 390.56M 87.08M
Long term investments 185.20M 58.13M 52.27M - -
Net tangible assets - 521.24M 578.73M 384.52M 77.82M
Short term investments 574.50M 755.51M 372.67M - -
Net receivables 5.29M 2.05M 0.73M - -
Long term debt 337.42M 335.48M - - -
Inventory - -2.04600M -0.72900M - -
Accounts payable 11.86M 10.06M 11.30M 4.99M 2.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.77M 3.10M -0.98600M -0.08200M -0.18200M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.01M 0.01M 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - -967.75500M -616.24400M -390.91000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.43M 4.76M 6.93M 6.09M 6.24M
Deferred long term asset charges - - - - -
Non current assets total 236.36M 112.17M 110.90M 54.71M 33.73M
Capital lease obligations 31.19M 34.09M 36.55M 33.01M 28.41M
Long term debt total - 335.48M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -384.88000M -425.15800M -18.89200M -1.09900M -425.15800M
Change to liabilities 30.04M 15.95M 1.42M 0.61M 5.01M
Total cashflows from investing activities -388.83400M -435.66100M -18.89200M -1.09900M -44.24800M
Net borrowings 353.13M 15.41M -1.78200M 334.77M -
Total cash from financing activities 623.19M 423.60M 440.83M 60.06M 454.20M
Change to operating activities 28.83M 8.26M 16.29M -0.26400M 2.48M
Net income -351.51100M -225.33400M -152.14200M -128.38900M -463.63600M
Change in cash -58.83000M -190.60500M 304.14M -11.76100M 381.77M
Begin period cash flow 197.22M 387.82M 83.68M 95.44M 8.10M
End period cash flow 138.39M 197.22M 387.82M 83.68M 95.44M
Total cash from operating activities -293.18700M -178.54600M -117.80200M -70.72000M -28.18000M
Issuance of capital stock 238.26M 328.25M 0.00000M 60.06M -
Depreciation 4.90M 2.73M 0.40M 0.18M 0.08M
Other cashflows from investing activities - -435.66100M -435.66100M -435.66100M -435.66100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 251.31M 383.71M - - -
Other cashflows from financing activities 384.93M 95.35M 435.31M -1.09900M 440.83M
Change to netincome 39.09M 46.79M 13.70M 57.15M 427.89M
Capital expenditures 3.95M 10.50M 18.89M 1.10M 44.25M
Change receivables - - - - -
Cash flows other operating -9.86800M 0.26M 11.31M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -58.83000M -190.60500M 304.14M - -
Change in working capital 28.06M 15.54M 17.71M 0.34M -
Stock based compensation 38.78M 23.94M 10.52M 8.31M -
Other non cash items -13.42300M 0.69M 2.44M 2.40M -
Free cash flow -297.14100M -189.04900M -136.69400M -71.81900M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CERE
Cerevel Therapeutics Holdings Inc		 - -% - - - - 11.28 -16.7649
NVO
Novo Nordisk A/S		 0.09 0.19% 47.51 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.79 0.61% 621.82 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Cerevel Therapeutics Holdings Inc

222 Jacobs Street, Cambridge, MA, United States, 02141

Key Executives

Name Title Year Born
Dr. N. Anthony Coles Jr., M.P.H. Exec. Chairman & CEO 1960
Mr. Abraham N. Ceesay M.B.A. Pres 1978
Mr. Mark Bodenrader Interim CFO, VP of Fin. & Chief Accounting Officer 1973
Mr. Scott M. Akamine J.D. Chief Legal Officer & Corp. Sec. 1985
Dr. Ramiro Sanchez M.D. Chief Medical Officer 1961
Dr. John J. Renger Ph.D. Chief Scientific Officer 1969
Mr. Matthew Calistri VP of Investor Relations NA
Mr. Kenneth A. DiPietro Chief HR Officer 1959
Ms. Kathleen Tregoning M.A. Chief Corp. Affairs Officer 1971
Dr. N. Anthony Coles Jr., M.P.H. Executive Chairman 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.